The Cystic Fibrosis Foundation employs a venture philanthropy model, investing in companies developing genetic therapies to address the underlying cause of cystic fibrosis and treatments to alleviate symptoms, with the ultimate goal of finding a cure for all individuals with the disease. Their strategy involves supporting a wide array of biotech companies, including those focused on gene editing, gene transfer, and gene delivery technologies, and reinvesting all financial returns into their mission.
100% of their portfolio is in Biotech & Life Sciences. They made 1 investments in the last 12 months. Their most common stage is series-a (67% of deals).
Portfolio
3
Fund Size
$5B
Top Stage
Series A
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
3 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| SSNIPR Biome | Series B | $35M | Aug 2025 |
 ViaNautis Bio | Series A | $25M | Nov 2023 |
| CCarmine Therapeutics | Series A | — | Oct 2022 |
Top Co-Investors
BGF1 shared
UCB1 shared
Eli Lilly and Company1 shared
Origin Ventures1 shared
Wellington Management1 shared
Last updated: 5 March 2026